These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2508448)

  • 1. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF).
    Barrett ML; Willis AL; Vane JR
    Agents Actions; 1989 Jun; 27(3-4):488-91. PubMed ID: 2508448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.
    Radomski MW; Palmer RM; Moncada S
    Br J Pharmacol; 1987 Sep; 92(1):181-7. PubMed ID: 3311265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin.
    Macdonald PS; Read MA; Dusting GJ
    Thromb Res; 1988 Mar; 49(5):437-49. PubMed ID: 3287674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.
    Radomski MW; Palmer RM; Moncada S
    Br J Pharmacol; 1987 Nov; 92(3):639-46. PubMed ID: 3322462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide and prostacyclin inhibit fetal platelet aggregation: a response similar to that observed in adults.
    Varela AF; Runge A; Ignarro LJ; Chaudhuri G
    Am J Obstet Gynecol; 1992 Dec; 167(6):1599-604. PubMed ID: 1471673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the existence and biological role of L-arginine/nitric oxide pathway in human platelets by spin-trapping/EPR studies.
    Prónai L; Ichimori K; Nozaki H; Nakazawa H; Okino H; Carmichael AJ; Arroyo CM
    Eur J Biochem; 1991 Dec; 202(3):923-30. PubMed ID: 1662618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries.
    Förstermann U; Mügge A; Alheid U; Bode SM; Frölich JC
    Eur Heart J; 1989 Nov; 10 Suppl F():36-43. PubMed ID: 2620689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets.
    Alheid U; Frölich JC; Förstermann U
    Thromb Res; 1987 Sep; 47(5):561-71. PubMed ID: 3499684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENDOTHELIUM-DERIVED INHIBITORS EFFICIENTLY ATTENUATE THE AGGREGATION AND ADHESION RESPONSES OF REFRIGERATED PLATELETS.
    Reddoch KM; Montgomery RK; Rodriguez AC; Meledeo MA; Pidcoke HF; Ramasubramanian AK; Cap AP
    Shock; 2016 Feb; 45(2):220-7. PubMed ID: 26555740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation.
    Golino P; Cappelli-Bigazzi M; Ambrosio G; Ragni M; Russolillo E; Condorelli M; Chiariello M
    Circ Res; 1992 Dec; 71(6):1447-56. PubMed ID: 1423938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
    Alheid U; Reichwehr I; Förstermann U
    Eur J Pharmacol; 1989 May; 164(1):103-10. PubMed ID: 2546782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors.
    Bassenge E
    Eur Heart J; 1991 Nov; 12 Suppl E():12-5. PubMed ID: 1665128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta.
    Bult H; Fret HR; Van den Bossche RM; Herman AG
    Br J Pharmacol; 1988 Dec; 95(4):1308-14. PubMed ID: 3064856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of platelet activation by endothelium-derived relaxing factor EDRF/NO and NO releasing dilator substances].
    Bassenge E
    Z Kardiol; 1991; 80 Suppl 5():17-21. PubMed ID: 1776330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelium-derived relaxant factor inhibits platelet activation.
    Busse R; Lückhoff A; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):566-71. PubMed ID: 2830546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man.
    Vallance P; Benjamin N; Collier J
    Eur J Clin Pharmacol; 1992; 42(1):37-41. PubMed ID: 1541315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of prostacyclin, EDRF and active oxygens in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro.
    Hirafuji M; Shinoda H
    Br J Pharmacol; 1993 Jun; 109(2):524-9. PubMed ID: 8358552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation.
    Furlong B; Henderson AH; Lewis MJ; Smith JA
    Br J Pharmacol; 1987 Apr; 90(4):687-92. PubMed ID: 3495310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.
    Stamler JS; Osborne JA; Jaraki O; Rabbani LE; Mullins M; Singel D; Loscalzo J
    J Clin Invest; 1993 Jan; 91(1):308-18. PubMed ID: 8380812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic disaggregation of platelets by the products of endothelial cells or their analogs.
    Suzuki Y; Takami H; Tamai Y; Narita M; Mayama K; Munakata A
    Haematologia (Budap); 2000; 30(2):81-90. PubMed ID: 10839560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.